| 1.47 -0.03 (-2%) | 04-07 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.9 | 1-year : | 2.37 |
| Resists | First : | 1.62 | Second : | 2.02 |
| Pivot price | 1.14  |
|||
| Supports | First : | 0.98 | Second : | 0.81 |
| MAs | MA(5) : | 1.3 |
MA(20) : | 1.11 |
| MA(100) : | 1.03 |
MA(250) : | 1.28 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 47.9 |
D(3) : | 36.3 |
| RSI | RSI(14): 74.5  |
|||
| 52-week | High : | 2.67 | Low : | 0.86 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ COCP ] has closed below upper band by 4.3%. Bollinger Bands are 273.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.52 - 1.53 | 1.53 - 1.54 |
| Low: | 1.33 - 1.34 | 1.34 - 1.35 |
| Close: | 1.45 - 1.47 | 1.47 - 1.48 |
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections; and drug discovery collaboration with HitGen and InterX Inc. The company is headquartered in Bothell, Washington.
Mon, 06 Apr 2026
Why Cocrystal Pharma Shares Are Cooling Off Monday? - Benzinga
Mon, 06 Apr 2026
COCP stock soars 75% — what is the link to Cocrystal’s norovirus treatment? - MSN
Sun, 05 Apr 2026
Cocrystal Pharma, Inc. (COCP) stock price, news, quote and history - Yahoo Finance UK
Sat, 04 Apr 2026
We're Keeping An Eye On Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Rate - simplywall.st
Fri, 03 Apr 2026
Cocrystal Pharma Shares Soar After FDA Grants Fast Track Status To CDI-988 - Sahm
Thu, 02 Apr 2026
Cocrystal Pharma (COCP) Receives FDA Fast Track Status for Norov - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 14 (M) |
| Shares Float | 9 (M) |
| Held by Insiders | 32.8 (%) |
| Held by Institutions | 5.5 (%) |
| Shares Short | 214 (K) |
| Shares Short P.Month | 236 (K) |
| EPS | -0.94 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.58 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -45.8 % |
| Return on Equity (ttm) | -95 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.4 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.71 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -10 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -1.59 |
| PEG Ratio | 0 |
| Price to Book value | 2.49 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.11 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|